Dawn Hill

Founder at MAP Patient Access Ltd.

Commercial Services

Profile

Dawn Hill has held a Non-Executive Director position at MAP Patient Access Ltd since 2012.
Additionally, she is the founder of MAP Patient Access Ltd, which was founded in 2012.

Dawn Hill active positions

Companies	Position	Start
MAP Patient Access Ltd. MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022.	Founder	31/12/2011

All active positions of Dawn Hill

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dawn Hill's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
MAP Patient Access Ltd. MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022.	Commercial Services